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Aim: In this randomized, double-blind, crossover study, we explored the acute effects on
respiratory function and safety of an additional dose of indacaterol 150 mg in stable COPD
patients regularly treated with a conventional dose of indacaterol 150 mg.
Methods: On two non-consecutive days, patients inhaled indacaterol 150 mg. After 180 min,
they inhaled an additional dose of indacaterol 150 mg or placebo. Lung function, oxygen satu-
ration by pulse oximetry (SpO2) and heart rate were measured before the first drug administra-
tion and up to 360 min thereafter.
Results: In both treatment groups, indacaterol induced a significant (P < 0.05) bronchodilation
during all the study time. The difference between the FEV1 AUCs0e180 min was not statistically
significant (PZ 0.971). On the contrary, the difference between the FEV1 AUCs180e360 min was
significant (P < 0.0001). However, only 8 out of 20 patients showed a further increase of at least
100 ml from the peak obtained after the first administration of indacaterol 150 mg with the second
dose of 150 mg. Indacaterol 150 mg induced a modest but significant decrease in SpO2 up to 60 min
and a seconddose of indacaterol 150mg significantly decreased the SpO2meanvalue up to 360min.
Conclusion: This study suggests that it is reasonable and safe to increase the dose of indacaterol in
those stableCOPDpatientswho are under regular therapywith indacaterol 150 mg fromwhich they
do not draw themaximumbenefit because they are unable to perceive bronchodilation. However,
only a minority of patients seem to benefit from this dose escalation, at least in terms of spiro-
metric improvement.
ª 2012 Elsevier Ltd. All rights reserved.of System Medicine, University of Rome ‘Tor Vergata’, Via Montpellier 1, 00133 Rome, Italy.
iroma2.it (M. Cazzola).
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108 M. Cazzola et al.Introduction consent to all procedures.Indacaterol is a novel once-daily ultra-long-acting b2-
adrenoceptor agonist bronchodilator now approved in many
Countries for maintenance bronchodilator treatment of
airflow obstruction in adult patients with COPD, to be
administered as 150 or 300 mg once-daily dose by means of
a single-dose dry powder inhaler. These two doses were
selected by an independent data monitoring committee
using pre-set efficacy criteria for trough (24-h post-dose)
and early (1e4 h post-dose) bronchodilator effect after 14
days, and all safety data.1 More specifically, the recom-
mended and usual dosage of indacaterol is the inhalation of
150 mg capsule once a day, using the Breezhaler (Novartis)
inhaler. Once a day inhalation of indacaterol 300 mg has
been shown to provide additional clinical benefit to some
patients,2,3 but the dosage should only be increased on
medical advice.
Usually, physicians recommend to increase the dose
when patients report the persistence of symptoms despite
they are under regular therapy with indacaterol 150 mg.
However, no studies have evaluated the risks and benefits
of this increase.
In the present pilot study, we explored the acute effects
on respiratory function of a further dose of indacaterol
150 mg in stable COPD patients regularly treated with the
conventional dose of indacaterol 150 mg. Moreover, we also
investigated whether this added dose was safe.Table 1 Demographics of the population studied.
Sex (no.) 18 M e 2 F
Age (years) 71.0  1.5
FEV1 (% predicted) 48.8  2.3
FVC (% predicted) 80.7  3.5
Reversibility (% from baseline) 9.3  1.2
Basal SpO2 (%) 95.8  0.4
Data are presented as mean  SE unless otherwise indicated. M,
male; F, female.Methods
We assessed 20 outpatients with moderate to severe COPD,
who were in a stable phase of the disease and were under
regular therapy with indacaterol 150 mg once a day from at
least 2 months. All patients reported a good compliance
with indacaterol before the study. They were 60 years of
age, current or former smokers (>10 pack-years) without
a history of asthmatic attacks, reporting chronic cough with
or without sputum production and/or dyspnea when
walking quietly on level ground. In addition, all patients
had FEV1 70% of predicted normal, and a best post-
bronchodilator FEV1/FVC of less than 0.7. Patients’ char-
acteristics and lung function data are given in Table 1.
Patients had experienced no change in symptom severity
or treatment in the preceding 2 months, had shown no signs
of a respiratory tract infection in the month preceding or
during the trial, and had not taken oral or inhaled corti-
costeroids, other inhaled or oral bronchodilators, leuko-
triene modifiers or b2-adrenoceptor blockers for at least 2
months. Patients with allergic rhinitis, atopy, and positive
skin test or with a total blood eosinophil count >400 mm3
were excluded. Patients were also excluded if they had any
coexisting cardiovascular or lung disorder, a resting PaO2 of
less than 60 mmHg, or use of long-term oxygen therapy.
Patients were asked to refrain from consumption of cola
drinks, coffee, tea, and from smoking, in the 12 h before
and also during the investigation.
The study, which was approved by the local Ethics
Committee, was conducted according to the rules of thedeclaration of Helsinki and each patient gave informed
A randomized, double-blind crossover design was used.
On two non-consecutive days, all patients, who continued
regular therapy with indacaterol 150 mg once a day, inhaled
their usual dose of indacaterol 150 mg Breezhaler. After
180 min they inhaled additional indacaterol 150 mg
Breezhaler (indacaterol arm) or placebo Breezhaler
(placebo arm). Lung function was controlled before the first
drug administration and 30, 60, 180, 210, 240, and 360 min
thereafter. At the same times, we also measured oxygen
saturation by pulse oximetry (SpO2) and heart rate. All
experiments began at 8 a.m. to avoid well-known inter-
ference of the circadian rhythm on bronchomotor tone.
As an expression of the total effect of each treatment,
the areas under the FEV1 responseetime curves (FEV1 AUC)
were calculated for each patient.
Spirometric data for each treatment were analyzed
using the Student’s t-test for paired variables. Mean
responses were also compared by multifactorial analysis of
variance (ANOVA) to establish any significant overall effect
between the two treatments. In the presence of a signifi-
cant overall ANOVA, Duncan’s multiple range testing with
95% confidence limits was used to identify where differ-
ences were significant. A probability level of P < 0.05 was
considered as significant for all tests. The areas under the
FEV1 response/time curves were analyzed by the trape-
zoidal rule.
The study had a power of 80% to detect a difference in
FEV1 of at least 110 ml between treatments. A joint Euro-
pean Respiratory Society/American Thoracic Society
statement concluded that the minimal important differ-
ence for FEV1 lies within a range of 100e140 ml.
4 For
comparison purposes, a difference of 100 ml has been re-
ported as the threshold at which a COPD patient can
perceive an effect.5
Results
All patients completed the 2-day study. There was no
significant difference between the baseline FEV1 values of
the two treatment groups (P > 0.05).
Changes in FEV1 and FVC values are shown in Figs. 1 and
2, respectively. In both treatment groups, indacaterol
induced a significant (P < 0.05) bronchodilation during all
the study time. The mean peak of the change in FEV1 from
baseline was observed after 180 min in the indacaterol
150 mg þ placebo arm, although it ranged from 30 min to
240 min. In the indacaterol 150 mg þ indacaterol 150 mg
arm, the mean peak of the change in FEV1 from baseline
Figure 2 Mean changes (SE) in FVC (L) from pre-dosing
value at different times after the inhalation of indacaterol
150 mg. At 180 min, patients inhaled placebo or an additional
dose of indacaterol 150 mg. *P < 0.05; **P < 0.01; and
***P < 0.001 vs. pre-dosing value.
1.4
1.6
1.8
2.0
E
V
1
,
 
L
A
Addition of an extra dose of indacaterol to COPD patients 109was observed after 360 min and it ranged from 30 min to
360 min.
The mean increases in FEV1 AUC0e360 min for all patients
were 0.58 (95% Cl: 0.40e0.77) L when indacaterol was
added and 0.47 (95% Cl: 0.28e0.66) L when placebo was
inhaled. The difference between the two arms was not
significant (P Z 0.073). Also the difference between the
FEV1 AUCs0e180 min (0.22 L, 95% Cl: 0.15e0.29; and 0.22 L,
95% Cl: 0.14e0.30, respectively) was not statistically
significant (P Z 0.971). On the contrary, the difference
between the FEV1 AUCs180e360 min (0.15, 95% Cl: 0.11e0.19;
and 0.05, 95% Cl: 0.09 to 0.00, respectively) was
significant (P < 0.0001).
Apparently, the baseline (predose) FEV1 value did not
influence the possibility of a further increase in FEV1 of at
least 100 ml after the extra dose of indacaterol. However,
only 8 out of 20 patients showed a further increase of at
least 100 ml from the peak obtained after the first admin-
istration of indacaterol 150 mg with the extra dose of
indacaterol 150 mg (Fig. 3).
The inhalation of indacaterol 150 mg did not significantly
increase the heart rate, but the addition of an extra dose of
indacaterol 150 mg induced a significant (P Z 0.035)
increase in heart rate at 360 min (Fig. 4). On the contrary,
the inhalation of indacaterol 150 mg induced a modest but
significant decrease in SpO2 up to 60 min and a second dose
of indacaterol 150 mg significantly decreased the SpO2 mean
value up to 360 min (Fig. 5). In any case, SpO2 never
decreased to less than 92%.Predose Ind150 Ind+Ind
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The results of our study suggest that the acute increase in the
dose of indacaterol with an additional dose of indacaterol
150 mg administered to patients with stable COPD who are
under regular treatment with indacaterol 150 mg once daily,
can give room for further increase in peak FEV1 in some of
them. This finding is not unexpected considering that Ren-
nard and co-workers6 showed that indacaterol (50, 100, 200
or 400 mg) caused a clear dose-dependent increase in FEV1.µ
Figure 1 Mean changes (SE) in FEV1 (L) from pre-dosing
value at different times after the inhalation of indacaterol
150 mg. At 180 min, patients inhaled placebo or an additional
dose of indacaterol 150 mg. **P < 0.01; and ***P < 0.001 vs. pre-
dosing value.
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Figure 3 Individual changes in FEV1 (L) from pre-dosing value
(predose) after the inhalation of indacaterol 150 mg (Ind150)
and that of an additional dose of indacaterol 150 mg
(Ind þ Ind). A: patients that showed a further increase of at
least 100 ml from the peak obtained after the first adminis-
tration of indacaterol 150 mg with the additional dose of
indacaterol 150 mg; B: patients that did not show a further
increase of at least 100 ml from the peak obtained after the
first administration of indacaterol 150 mg with the additional
dose of indacaterol 150 mg.
Figure 4 Mean changes (SE) in heart rate (beats/min) from
pre-dosing value at different times after the inhalation of
indacaterol 150 mg. At 180 min, patients inhaled placebo or an
additional dose of indacaterol 150 mg. *P < 0.05 vs. pre-dosing
value.
110 M. Cazzola et al.As already mentioned, indacaterol has been approved in
many Countries (including throughout the European Union)
for use in COPD at the dose of 150 mg once daily, dose that
can be increased on medical advice to a maximum of 300 mg
once daily, although in Phase II dose-ranging studies in
COPD, indacaterol consistently demonstrated bronchodi-
lator efficacy that was superior to placebo, regardless of
the dose tested.6,7 In effect, a comprehensive assessment
of the bronchodilatory dose response of indacaterol in
COPD patients has provided a robust confirmation that
75 mg is the minimum effective dose, and that 150 and
300 mg are expected to provide optimal bronchodilation,
mainly in COPD patients with baseline FEV1 less than 1 L.
8
Our data indicate that patients suffering from COPD, who
are taking indacaterol 150 mg as regular maintenance
therapy, may increase the dose of indacaterol if it is needed,
although only a proportion of patients with COPD seem to
require a dose escalation, while in many patients this
increase does not induce any substantial improvement in
lung function. This finding can probably be attributed to theFigure 5 Mean changes (SE) in pulse oximetry (SpO2) (%)
from pre-dosing value at different times after the inhalation of
indacaterol 150 mg. At 180 min, patients inhaled placebo or an
additional dose of indacaterol 150 mg. *P < 0.05; **P < 0.01;
and ***P < 0.001 vs. pre-dosing value.high FEV1 values that we have observed 3 h after the inha-
lation of the first dose of indacaterol, which left relatively
little room for bronchodilator improvement in response to an
additional dose of indacaterol. In effect, each patient with
COPD has his/her own optimal function that is regarded to be
the best lung function that patients can achieve either
spontaneously or as a result of the treatment.9 It is
conceivable that many of our patients, who were in stable
clinical condition and under regular therapywith indacaterol
150 mg, were near the top of their bronchodilation response
after inhalation of the first dose of indacaterol 150 mg also
because under regular therapy with this bronchodilator.
Alternatively, we could postulate that, since our patients
were under chronic administration of indacaterol, a subse-
quent reduced sensitivity of b2-adrenoceptors was a possi-
bility in some patients. However, no tachyphylaxis has been
demonstrated for indacaterol, at least in guinea pig.10
Moreover, tachyphylaxis and tolerance have not been
observed with long-term indacaterol administration.11e13
Our data also suggest that only a proportion of patients
with COPD require such additional dose while in many
patients an additional dose does not induce any substantial
improvement in lung function. In any case, it must be
highlighted that the population in our study was small and
the results were measured only once. We do not know
whether the findings of our study were reproducible in the
same subjects or they were random noise. In effect, poor
responders could have been good responders on a second
day. This is a possibility that we have not tested because we
aimed to understand what happens soon after our decision
to increase the dose of indacaterol. In real life, the bron-
chodilator response that we record can influence our choice
of continuing with a higher dose and/or the compliance of
our patient to the increased dose.
In any case, apparently, the baseline FEV1 value does not
seem to influence the possibility of a further increase in
FEV1 of at least 100 ml after an additional dose of indaca-
terol 150 mg. This finding is in contrast with what reported
by Renard and co-workers.8
The lack of effects on heart rate that we have recorded in
this study even when the dose of indacaterol has been
increased, confirms cardiac safety of this b-adrenoceptor
agent. It is important to highlight that Holter monitoring in
some clinical trials in some clinical trials proved that mean
heart rate does not differ in a statistically significant manner
among the treatments (indacaterol 150 and 300 mg, and
placebo).14
In our study, indacaterol induced small but statistically
significant modifications in SpO2. Because of the lack of
sensitivity of the technique, we cannot exclude that these
small variations in SpO2, could result in mild hypoxemia.
15 It
is well known that the administration of b-adrenoceptor
agents to patients with airway obstruction often results in
a transient decrease in oxygen partial pressure (PaO2)
despite concomitant bronchodilation.16 However, we must
mention that all our patients had a resting PaO2 higher than
60 mm Hg and SpO2 never decreased to less than 92% after
indacaterol, even when we increased the dose. It is likely
that the small modifications in SpO2 that we have recorded
had no real clinical impact. Nonetheless, we believe that
a study focused on the impact of different doses of inda-
caterol on blood gases is now mandatory.
Addition of an extra dose of indacaterol to COPD patients 111In conclusion, this study suggests that it is reasonable and
safe to increase the dose of indacaterol in those COPD
patients who are under regular therapy with indacaterol
150 mg from which they do not draw the maximum benefit
because they are unable to perceive bronchodilation.
However, only aminority of patients seem tobenefit from this
dose escalation, at least in terms of spirometric improve-
ment. A study designed to assess the long-term effects of the
indacaterol dose escalation in COPD patients already
receiving regular therapy with 150 mg indacaterol is impera-
tive inorder tounderstandwhocanbenefit fromthis increase.
For this purpose, the study will not only focus on respiratory
function but will explore patient-reported outcomes.4Conflict of interest statement
We declare that we have no conflict of interest with this
study that has not been sponsored by any Drug Company.References
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